Page last updated: 2024-11-04

2-aminothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-aminothiazole: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2155
CHEMBL ID344760
CHEBI ID40782
SCHEMBL ID7401
MeSH IDM0045561

Synonyms (137)

Synonym
thiazol-2-yl-amine
nsc-1900
basedol
2-thiazolylamine
thiazole, 2-amino-
2-thiazylamine
wln: t5n csj bz
2-thiazolamine
abadol
abadole
4-thiazolin-2-onimine
2-aminothiazole
rp 2921
nsc1900
96-50-4
usaf ek-p-5501
AMINOTHIAZOLE ,
KBIO1_000176
DIVK1C_000176
AB-601/30915002
1,3-thiazol-2-ylamine
SPECTRUM_000085
SPECTRUM5_000973
BSPBIO_003414
IDI1_000176
thiazol-2-amine
thiazole,2-amino
inchi=1/c3h4n2s/c4-3-5-1-2-6-3/h1-2h,(h2,4,5
1,3-thiazol-2-amine
NCGC00091162-01
aminotiazol [inn-spanish]
aminotiazolo [dcit]
einecs 202-511-6
aminothiazolum [inn-latin]
cp 1585
nsc 1900
aminothiazole [inn]
aminothiazol [inn-french]
ai3-14917
ccris 1279
aminothiazole (inn)
D02479
2-aminothiazole, 97%
NCGC00091162-02
NCGC00091162-03
KBIO2_003073
KBIO2_005641
KBIO3_002634
KBIOSS_000505
KBIOGR_001028
KBIO2_000505
SPECTRUM2_000879
SPBIO_000957
SPECTRUM4_000734
SPECTRUM3_001737
NINDS_000176
SPECTRUM1503017
NCGC00091162-04
STK387115
aminothiazoline
thiazol-2-ylamine
bdbm50240843
A0633
chebi:40782 ,
CHEMBL344760 ,
rp-2921
HMS500I18
HMS1922A05
AKOS000119189
NCGC00091162-06
NCGC00091162-05
2-aminothiazol
unii-5k8wkn668k
aminothiazolum
aminothiazol
aminotiazolo
5k8wkn668k ,
aminotiazol
tox21_200726
NCGC00258280-01
2-amino thiazole
pharmakon1600-01503017
nsc-758210
nsc758210
dtxsid5024508 ,
dtxcid604508
cas-96-50-4
tox21_111093
S4198
CCG-40298
29385-37-3
thiazolamine
2-amino-1,3-thiazole
FT-0611274
AM20120385
2-aminothiazole [mi]
BP-21217
SCHEMBL7401
CS-3404
2-imino-2,3-dihydro-1,3-thiazole
2-amino-thiazole
2-amino thiozol
thiazole amine
2-amino-thiazol
1,3-thiazole-2-amine
2-aminothiozole
thiazolyl amine
amino thiazol
thiazole-2-amine
amino-1,3-thiazole
2-amino-1,3 thiazole
NCGC00091162-07
1,3-thiazol-2-amine #
W-100142
STR00409
361381-86-4
PS-9323
HY-12396
AB00052300_04
AB00052300_03
mfcd00005325
F2146-0059
SR-01000872739-1
sr-01000872739
2-iminothiazole
2-aminothiazol, technical, >=90% (nt)
HMS3652B11
AC7847
SBI-0051751.P002
SY001447
SW219866-1
Q2746995
A16403
n-(2-nitrophenyl)cyanamide
NCGC00091162-09
EN300-19107
Z104472798

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Absolute bioavailability ranged from 27-40%."( Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.
Benet, LZ; Dalvie, DK; Elepano, M; Fife, KL; Freyman, Y; Gallardo-Godoy, A; Gever, JR; Giles, K; Huang, Y; Jacobson, MP; Li, Z; Prusiner, SB; Rao, S; Renslo, AR; Silber, BM, 2013
)
0.67
"Recently, we described the aminothiazole lead (4-biphenyl-4-ylthiazol-2-yl)-(6-methylpyridin-2-yl)-amine (1), which exhibits many desirable properties, including excellent stability in liver microsomes, oral bioavailability of ∼40 %, and high exposure in the brains of mice."( 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.
Bryant, C; Dolghih, E; Elepano, M; Gallardo-Godoy, A; Gever, JR; Jacobson, MP; Li, Z; Prusiner, SB; Rao, S; Renslo, AR; Silber, BM; Widjaja, K, 2013
)
1.83
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
1,3-thiazoles
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.96890.006038.004119,952.5996AID1159521
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
GLI family zinc finger 3Homo sapiens (human)Potency0.38570.000714.592883.7951AID1259369
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
Cellular tumor antigen p53Homo sapiens (human)Potency0.26600.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nitric oxide synthase, brainHomo sapiens (human)Ki12.00000.01501.18117.3000AID404423
Nitric oxide synthase, inducibleMus musculus (house mouse)IC50 (µMol)18.00000.00103.39119.6000AID344879; AID408488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (156)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to hypoxiaNitric oxide synthase, brainHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, brainHomo sapiens (human)
arginine catabolic processNitric oxide synthase, brainHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, brainHomo sapiens (human)
striated muscle contractionNitric oxide synthase, brainHomo sapiens (human)
myoblast fusionNitric oxide synthase, brainHomo sapiens (human)
response to heatNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transport into cytosolNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingNitric oxide synthase, brainHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, brainHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNitric oxide synthase, brainHomo sapiens (human)
multicellular organismal response to stressNitric oxide synthase, brainHomo sapiens (human)
xenobiotic catabolic processNitric oxide synthase, brainHomo sapiens (human)
vasodilationNitric oxide synthase, brainHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, brainHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, brainHomo sapiens (human)
positive regulation of DNA-templated transcriptionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINitric oxide synthase, brainHomo sapiens (human)
negative regulation of hydrolase activityNitric oxide synthase, brainHomo sapiens (human)
negative regulation of serotonin uptakeNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contractionNitric oxide synthase, brainHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityNitric oxide synthase, brainHomo sapiens (human)
cellular response to growth factor stimulusNitric oxide synthase, brainHomo sapiens (human)
positive regulation of the force of heart contractionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNitric oxide synthase, brainHomo sapiens (human)
positive regulation of sodium ion transmembrane transportNitric oxide synthase, brainHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelNitric oxide synthase, brainHomo sapiens (human)
positive regulation of membrane repolarization during ventricular cardiac muscle cell action potentialNitric oxide synthase, brainHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, brainHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, brainHomo sapiens (human)
response to hormoneNitric oxide synthase, brainHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, brainHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, brainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, brainHomo sapiens (human)
calcium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
protein bindingNitric oxide synthase, brainHomo sapiens (human)
calmodulin bindingNitric oxide synthase, brainHomo sapiens (human)
FMN bindingNitric oxide synthase, brainHomo sapiens (human)
sodium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
heme bindingNitric oxide synthase, brainHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, brainHomo sapiens (human)
arginine bindingNitric oxide synthase, brainHomo sapiens (human)
transmembrane transporter bindingNitric oxide synthase, brainHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, brainHomo sapiens (human)
calcium-dependent protein bindingNitric oxide synthase, brainHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, brainHomo sapiens (human)
NADP bindingNitric oxide synthase, brainHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, brainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
photoreceptor inner segmentNitric oxide synthase, brainHomo sapiens (human)
nucleoplasmNitric oxide synthase, brainHomo sapiens (human)
cytoplasmNitric oxide synthase, brainHomo sapiens (human)
mitochondrionNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
cytoskeletonNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
sarcoplasmic reticulumNitric oxide synthase, brainHomo sapiens (human)
sarcolemmaNitric oxide synthase, brainHomo sapiens (human)
dendritic spineNitric oxide synthase, brainHomo sapiens (human)
membrane raftNitric oxide synthase, brainHomo sapiens (human)
synapseNitric oxide synthase, brainHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, brainHomo sapiens (human)
cell peripheryNitric oxide synthase, brainHomo sapiens (human)
protein-containing complexNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
postsynaptic densityNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, brainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1365100Haemostatic activity in human plasma assessed as change in rate of prothrombin time at 5 uM after 3 mins by thromboplastic agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID756686Activation of AMPKalpha in rat L6 cells assessed as phosphorylation at Thr172 after 40 mins to 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID344879Inhibition of iNOS in mouse ANA1 cells2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
AID1365105Haemostatic activity in human plasma assessed as change in rate of activated partial thromboplastin time at 5 uM after 3 mins relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1852930Thiol reactivity of compound at 100 uM measured by DTNB assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365102Haemostatic activity in human plasma assessed as change in rate of prothrombin time at 50 uM after 3 mins by thromboplastic agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1365110Haemostatic activity in human plasma assessed as change in rate of thrombin time at 5 uM after 3 mins by thrombin agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1852920Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins in presence of 1mM DTT followed by substrate addition and2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365101Haemostatic activity in human plasma assessed as change in rate of prothrombin time at 10 uM after 3 mins by thromboplastic agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1852921Inhibition of Mycobacterium tuberculosis MetAP1a assessed as residual activity at 625 uM using L-methionine 7-amido-4-methylcoumarin as fluorogenic substrate and measured by fluorescence based assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852926Redox activity of compound assessed as redox index at 100 uM measured by H2DCFDA assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852927Redox activity of compound assessed as redox index at 100 uM in presence of 100 uM TCEP measured by H2DCFDA assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID408488Inhibition of inducible nitric oxide synthetase in LPS-stimulated mouse ANA1 macrophages2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase.
AID1852929Redox activity of compound assessed as redox index at 1 uM measured by resazurin assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365103Haemostatic activity in human plasma assessed as change in rate of prothrombin time at 100 uM after 3 mins by thromboplastic agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1365112Haemostatic activity in human plasma assessed as change in rate of thrombin time at 50 uM after 3 mins by thrombin agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID756690Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs relative to control2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID1852928Redox activity of compound assessed as redox index at 10 uM measured by resazurin assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1365098Inhibition of ADP-induced platelet aggregation in human plasma2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1365099Haemostatic activity in human plasma assessed as change in rate of prothrombin time at 1 uM after 3 mins by thromboplastic agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1365111Haemostatic activity in human plasma assessed as change in rate of thrombin time at 10 uM after 3 mins by thrombin agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1365108Haemostatic activity in human plasma assessed as change in rate of activated partial thromboplastin time at 100 uM after 3 mins relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1852923Aqueous stability of the compound at pH 7.4 measured after 60 mins by spectrophotometric analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852925Redox activity of compound assessed as redox index at 100 uM in presence of 1 mM DTT measured by HRP-PR assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365109Haemostatic activity in human plasma assessed as change in rate of thrombin time at 1 uM after 3 mins by thrombin agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1365107Haemostatic activity in human plasma assessed as change in rate of activated partial thromboplastin time at 50 uM after 3 mins relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID80631Percent relaxation of isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID1852931Thiol reactivity of compound measured by TNB2- assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852919Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured by FRET assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365104Haemostatic activity in human plasma assessed as change in rate of activated partial thromboplastin time at 1 uM after 3 mins relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1365106Haemostatic activity in human plasma assessed as change in rate of activated partial thromboplastin time at 10 uM after 3 mins relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID1852922Inhibition of recombinant Escherichia coli DdlB assessed as residual activity at 500 uM using D-alanine as substrate incubated for 20 mins and measured by malachite green based colorimetric assay relative to control2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID404423Inhibition of nNOS assessed as conversion of L-[3H]arginine to L-[3H]citrulline2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase.
AID1852916Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate and measured by malachite green based colorimetric assay relative to control2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1852917Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins in presence of 1 mM DTT followed by substrate addition and measured by malachite green based colori2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1365113Haemostatic activity in human plasma assessed as change in rate of thrombin time at 100 uM after 3 mins by thrombin agent based assay relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID756681Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs in presence of insulin2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID80624Percent relaxation using isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID1852924Redox activity of compound assessed as redox index at 100 uM measured by HRP-PR assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1852915Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins followed by substrate addition and measured by malachite green based colorimetric assay relative to2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (6.38)18.7374
1990's5 (3.55)18.2507
2000's26 (18.44)29.6817
2010's69 (48.94)24.3611
2020's32 (22.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.86 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index72.27 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (6.34%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (93.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]